Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)

Guardant Health, Inc.

2024-FY EPS reported -$3.56 revenue$739,016,000

Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).
Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).
Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).
Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.
Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.